Last edition
News about "Dr. Randall Marshall"
EuMentis Therapeutics Secures US FDA Clearance of IND Application for EM-221
EuMentis Therapeutics has received FDA clearance to initiate a Phase 2 clinical trial of EM-221, its novel PDE10A inhibitor, for the treatment of schizophrenia.
Dr. Randall Marshall | 31/07/2025 | By Mrinmoy Dey | 106
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members